COMPANY

Marengo Therapeutics

HQ: Cambridge, MA source · marengotx.com ↗

Keywords: oncology cancer Female Genital Neoplasm Urogenital Neoplasms Lung Neoplasm Neoplasms by Site Papillomavirus Infection Epstein-Barr Virus Infections Vulvar Neoplasms Vulvar Diseases Abdominal Neoplasm NSCLC (Non-small Cell Lung Cancer) Colorectal Cancer Triple Negative Locally Advanced Non-resectable Breast Cancer HR+, HER2-, Advanced Breast Cancer STAR0602

Location: Cambridge, MA · source · Oct 12, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

Mar 24, 2025 Trial start Phase 1/Phase 2: A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants Wi source ↗
Mar 3, 2025 Partnership Partnership / licensing announced Mar 3, 2025. Source: company's own press page. source ↗
Jan 4, 2023 Trial start Phase 1/Phase 2: A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors source ↗

Upcoming milestones

2027-01 (ESTIMATED) · Phase 1/Phase 2 · A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid · NCT06827613
2027-09 (ESTIMATED) · Phase 1/Phase 2 · A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors · NCT05592626

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Mar 3, 2025 Partnership / licensing announced Mar 3, 2025. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT05592626	A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors	Phase 1/Phase 2	Recruiting	Jan 4, 2023	2027-09 (estimated)
NCT06827613	A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors	Phase 1/Phase 2	Recruiting	Mar 24, 2025	2027-01 (estimated)